More stories
PT386 – Vital Psychedelic Conversations
In this episode, David once again interviews a teacher and student from Vital, speaking with Grof-certified Holotropic Breathwork® practitioner, author, and developer of InnerEthics®:...
PharmaTher Holdings Announces FDA Grant of Orphan Drug Designation to KETARX™ (Ketamine) for the...
PharmaTher’s 5th FDA orphan drug designation for KETARX (ketamine) Phase 2 clinical study results to support proposed Phase 3 development of KETARX (ketamine) to...
Silo Pharma Announces Expansion of Intellectual Property Portfolio
ENGLEWOOD CLIFFS, NJ, Feb. 02, 2023 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging...
Ehave Provides Progress Update on its HPPD Study with University of Melbourne
MIAMI, Feb. 02, 2023 (GLOBE NEWSWIRE) — Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a Healthcare Analytics provider with interests in the psychedelic and...
Reunion Neuroscience Schedules Fiscal Third Quarter 2023 Conference Call for Tuesday, February 14, 2023,...
TORONTO, Feb. 02, 2023 (GLOBE NEWSWIRE) — Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or “the Company”), a biopharmaceutical company committed to developing...
Mindset Pharma Receives Another Allowance from USPTO for Patent Application Expanding Composition of Matter...
TORONTO, Feb. 02, 2023 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery company...
The Agenda for Economic Analyses of Psychedelic-assisted Therapy
Global Initiative for Psychedelic Science Economics (GIPSE) Part of our Year in Review series Elliot Marseille DrPH, MPP, Stefano Bertozzi, MD, PhD, and James...
A Perspective on Providers: Scaling PAT in a Time of Therapist Shortages
Director of Program Operations, BrainFutures Part of our Year in Review series Jazz Glastra is the Director of Program Operations for BrainFutures, a nonprofit...
Making “Access” A Meaningful Part of Every Conversation about Psychedelic Therapy
Associate Dean for Research and Associate Professor, Columbia University School of Social Work Part of our Year in Review series Heidi Allen, MSW, PhD,...
Psychedelic Therapies: From Approvals to Access
Achieving approval for a psychedelic-assisted therapy (PAT) would be a significant milestone. However, given the complexities and costs associated with PATs, they won’t fit...
PharmaTher Holdings Submits FDA Meeting Package to Discuss Phase 3 Program and Fast Track...
TORONTO, Feb. 01, 2023 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in advancing specialty ketamine...
Small Pharma Announces Update on Intellectual Property Portfolio with Two New Patents Approved for...
New United States patents will provide further support for the Company’s proprietary position in a key jurisdiction United States grants will bring the Company’s...
